PMID- 36148493
OWN - NLM
STAT- MEDLINE
DCOM- 20221202
LR  - 20230324
IS  - 1751-2980 (Electronic)
IS  - 1751-2972 (Linking)
VI  - 23
IP  - 8-9
DP  - 2022 Aug
TI  - Clinical outcomes of hepatic arterial infusion chemotherapy combined with 
      tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable 
      intrahepatic cholangiocarcinoma.
PG  - 535-545
LID - 10.1111/1751-2980.13127 [doi]
AB  - OBJECTIVE: To compare the treatment efficacy and safety of tyrosine kinase 
      inhibitors (TKIs) and anti-programmed cell death 1 (PD-1) immunotherapy combined 
      with transarterial chemoembolization (TACE) or hepatic arterial infusion 
      chemotherapy (HAIC) for patients with unresectable intrahepatic 
      cholangiocarcinoma (ICC). METHODS: Patients with unresectable ICC received TKIs 
      and anti-PD-1 immunotherapy combined with HAIC (HTP group) or TACE (TTP 
      group) were included. The clinicopathological characteristics, treatment 
      efficacy, and adverse events (AEs) were compared between the two groups. The 
      factors associated with response rate to the treatments were evaluated. RESULTS: 
      A total of 58 patients were enrolled, with 39 in the HTP group and 19 in the TTP 
      group. Patients in the HTP group exhibited a better objective response rate (ORR; 
      Response Evaluation Criteria in Solid Tumors [RECIST] 48.7% vs 15.8%, P = 0.02; 
      modified RECIST [mRECIST] 61.5% vs 21.1%, P = 0.004) and disease control rate 
      (DCR; 82.1% vs 36.8%, P = 0.001) compared to the TTP group. The median 
      progression-free survival (PFS) rate was not reached and the 1-year PFS rate was 
      61.9% in the HTP group, whereas the median PFS was 11.0 months and the 1-year PFS 
      rate was 31.6% in the TTP group. The type of treatment and tumor size were 
      significant factors for the response rate. More patients in the HTP group 
      presented rash, abdominal pain and hand-foot syndrome, but all AEs were relieved 
      after symptomatic treatment, and no treatment-related death occurred. 
      CONCLUSIONS: For unresectable ICC, treatment with a combination of HAIC with TKIs 
      and anti-PD-1 immunotherapy was effective and safe. Tumor size might serve as a 
      significant factor for the response rate following treatment for unresectable 
      ICC.
CI  - (c) 2022 Chinese Medical Association Shanghai Branch, Chinese Society of 
      Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University 
      School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Zhang, Ning
AU  - Zhang N
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Yu, Bing Ran
AU  - Yu BR
AUID- ORCID: 0000-0003-2239-7531
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Wang, Yi Xiu
AU  - Wang YX
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Zhao, Yi Ming
AU  - Zhao YM
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Zhou, Jia Min
AU  - Zhou JM
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Wang, Miao
AU  - Wang M
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Wang, Long Rong
AU  - Wang LR
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Lin, Zhen Hai
AU  - Lin ZH
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Zhang, Ti
AU  - Zhang T
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Hepatic Surgery, Shanghai Cancer Center, Shanghai Medical College, 
      Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20221113
PL  - Australia
TA  - J Dig Dis
JT  - Journal of digestive diseases
JID - 101302699
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Bile Ducts, Intrahepatic/pathology
MH  - *Bile Duct Neoplasms/drug therapy
MH  - *Carcinoma, Hepatocellular/therapy
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - *Cholangiocarcinoma/drug therapy
MH  - Treatment Outcome
MH  - Immunotherapy/adverse effects
MH  - Protein Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - anti-PD-1 immunotherapy
OT  - hepatic arterial infusion chemotherapy
OT  - intrahepatic cholangiocarcinoma
OT  - tyrosine kinase inhibitors
EDAT- 2022/09/24 06:00
MHDA- 2022/12/03 06:00
CRDT- 2022/09/23 03:02
PHST- 2022/08/12 00:00 [revised]
PHST- 2022/06/21 00:00 [received]
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/12/03 06:00 [medline]
PHST- 2022/09/23 03:02 [entrez]
AID - 10.1111/1751-2980.13127 [doi]
PST - ppublish
SO  - J Dig Dis. 2022 Aug;23(8-9):535-545. doi: 10.1111/1751-2980.13127. Epub 2022 Nov 
      13.